Inavolisib
- Generic Name
- Inavolisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19F2N5O4
- CAS Number
- 2060571-02-8
- Unique Ingredient Identifier
- L4C1UY2NYH
- Background
Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04632992
- Locations
- 🇺🇸
Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
🇺🇸Ascension St. John Hospital, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 920
- Registration Number
- NCT04589845
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
CRAFT: the NCT-PMO-1602 Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 175
- Registration Number
- NCT04551521
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany
🇩🇪Universitätsklinikum Freiburg, Freiburg, Germany
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
🇺🇸Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT04449874
- Locations
- 🇺🇸
UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 325
- Registration Number
- NCT04191499
- Locations
- 🇪🇸
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
🇪🇸Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain
🇪🇸Hospital del Mar; Servicio de Oncologia, Barcelona, Spain
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03006172
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.